Clinical Trial of Eribulin in Combination with Anrotinib for HER-2 Negative Locally Advanced or Metastatic Breast Cancer

NCT ID: NCT06678230

Last Updated: 2024-11-07

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: PHASE2
• Total Enrollment: 40 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-11-30
• Study Completion Date: 2025-10-20

Brief Summary

Study Objective: To evaluate the progression-free survival of HER-2 negative locally advanced or metastatic breast cancer subjects treated with eribulin in combination with erlotinib Trial Drug: Erlotinib Targets: Erlotinib is a novel small-molecule multi-targeted tyrosine kinase inhibitor, which can inhibit the kinase activities of vascular endothelial growth factor receptor (VEGFR1-3), platelet-derived growth factor receptor (PDGFRα, PDGFRβ), fibroblast growth factor receptor (FGFR1-4), stem cell growth factor receptor, etc., and thus exert anti-tumor angiogenesis, thereby exerting anti-tumor angiogenesis and anti-vascularity. PDGFRα, PDGFRβ), fibroblast growth factor receptor (FGFR1-4), stem cell growth factor receptor and other kinase activities, and then play the role of anti-tumor angiogenesis and inhibition of tumor growth. Results of previous studies, known efficacy and adverse effects: The single-agent regimen of amlotinib has been clinically approved in non-small cell lung cancer, gastric cancer, and soft tissue sarcoma. In breast cancer, the II clinical study of amlotinib monotherapy for the treatment of HER-2 negative advanced breast cancer in the second line and above showed that the PFS of amlotinib monotherapy was 5.22 months, ORR was 15.4%, and DCR was 80.8%, which demonstrated that amlotinib has better anti-tumor activity. Major adverse reactions: fatigue, weight loss, hypertension, diarrhea, nausea, vomiting, hematemesis

Detailed Description

This is a single-arm, single-center, Phase II clinical trial of eribulin in combination with amlotinib in subjects with HER-2 negative locally advanced or metastatic breast cancer.

The trial is planned to enroll 40 subjects with HER-2 negative locally advanced or metastatic breast cancer who have received prior chemotherapy with anthracycline and paclitaxel-based agents to receive eribulin in combination with erlotinib.

Trial drug: eribulin 1.4 mg/m2, D1,8; one cycle every 3 weeks; Amlotinib 12 mg, QD, po, applied for 14 days and stopped for 7 days, one cycle every 3 weeks.

All subjects will receive long-term dosing until intolerable toxicity or disease progression or death or voluntary withdrawal or the end of this trial (meaning completion of the trial or early termination of the trial).

During the treatment period, all subjects will be evaluated for antitumor efficacy every 6 weeks and disease status will be determined by the investigator according to RECIST 1.1 criteria until disease progression or death or refusal to come to the hospital for follow-up or the end of the trial (meaning completion of the trial or early termination of the trial), whichever event occurs first. After a subject's disease progression or refusal to come to the hospital for follow-up, the investigator will make a telephone visit every 3 months (each month will be counted as 30 days) to obtain information about the subject's survival, whether he/she is receiving other antitumor therapy, etc.

Conditions

Breast Cancer

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

This is a single-arm, single-center, phase II clinical trial of eribulin in combination with erlotin

This trial is planned to enroll 40 subjects with HER-2 negative locally advanced or metastatic breast cancer who have received prior chemotherapy with anthracyclines and paclitaxel, treated with eribulin in combination with erlotinib.

Trial drug: eribulin 1.4 mg/m2, D1,8; one cycle every 3 weeks; Amlotinib 12 mg, QD, po, applied for 14 days and stopped for 7 days, one cycle every 3 weeks.

All subjects will receive long-term dosing until intolerable toxicity or disease progression or death or voluntary withdrawal or the end of this trial (meaning completion of the trial or early termination of the trial).

During the treatment period, all subjects will be evaluated for antitumor efficacy every 6 weeks and disease status will be determined by the investigator according to RECIST 1.1 criteria until disease progression or death or refusal to come to the hospital for follow-up or the end of the trial (meaning completion of the trial or early termination of the trial), whichever event occurs

Group Type: EXPERIMENTAL

Anlotinib

Intervention Type: DRUG

Alibulin 1.4mg/m2, D1, 8; Every 3 weeks is a cycle; Androtinib 12mg, QD, po, applied for 14 days, stopped for 7 days, and every 3 weeks was a cycle.

Interventions

Anlotinib

Alibulin 1.4mg/m2, D1, 8; Every 3 weeks is a cycle; Androtinib 12mg, QD, po, applied for 14 days, stopped for 7 days, and every 3 weeks was a cycle.

Intervention Type: DRUG

Other Intervention Names

Eribulin

Eligibility Criteria

Inclusion Criteria

• histologically or cytologically confirmed breast cancer.
• immunohistochemistry HER-2 negative at this center
• subjects with locally recurrent or metastatic breast cancer who have received chemotherapy with anthracyclines and paclitaxel prior to the current chemotherapy regimen. Treatment prior to study entry must meet the following criteria: a. The regimen must include anthracyclines (e.g., doxorubicin, epirubicin, piroxicam) and paclitaxel (e.g., paclitaxel, docetaxel) in any combination or other order of administration. If these drugs are contraindicated in the intended subject, prior use of these drugs in prior therapy is not required but is documented in the subject's medical history. b. Some of these regimens may be used as adjuvant and/or neoadjuvant therapies, and subjects may also have been previously treated with anti-estrogenic agents. c. ≤2 lines of chemotherapy targeting recurrent/metastatic lesions: i Anthracyclines and paclitaxel adjuvant therapy within 12 months of progression; ii progression on advanced first/second line therapy; iii subjects must have demonstrated disease progression on the most recent chemotherapy.
• Endocrine therapy targeting recurrent/metastatic lesions will not be counted towards the number of lines of therapy.

Exclusion Criteria

• Age ≥ 18 and ≤ 70 years at the time of signing the informed consent form.
• Appropriate renal function as evidenced by serum creatinine ≤ 2.0 mg/dL, or serum creatinine clearance ≥ 40 mL/min according to the Cockcroft-Gault formula.
• Absolute Neutrophil Count (ANC) ≥ 1.5 x 109/L, hemoglobin ≥ 9.0 g/dL, and platelet count ≥ 100 x 109/L as evidence of adequate bone marrow function.
• Bilirubin ≤ 1.5 times the upper limit of normal (ULN); and alkaline phosphatase (ALP), alanine aminotransferase (ALT), and aspartate aminotransferase (AST) ≤ 3.0 times the ULN (≤ 5.0 times the ULN in the case of hepatic metastases) as evidence of adequate bone marrow function. 5.0 times upper limit of normal) as evidence of appropriate liver function.
• Subjects are willing and able to comply with the study protocol throughout the study period.
• All female subjects will be considered of childbearing potential unless postmenopausal (at least 12 consecutive months of amenorrhea, in the appropriate age group, and with no other known or suspected cause) or surgically sterilized (i.e., ≥1 menstrual cycle of bilateral tubal ligation, or hysterectomy and/or bilateral oophorectomy prior to randomization). Female subjects of childbearing potential must agree to use two highly effective methods of contraception beginning with their last menstrual period prior to randomization grouping (or until two highly effective methods of contraception have been used for at least one menstrual cycle using the double-barrier method described below), during the study period, and for a period of 3 months after the final dose of study treatment. Female subjects exempted from this requirement were subjects who were completely abstinent. If currently abstinent, the subject must agree to use a double barrier method of contraception (i.e., condom with spermicide and an occlusive cap (uterine cap or cervical/vault cap)) if she becomes sexually active during the study treatment period, or two highly effective methods of contraception for at least one menstrual cycle and until 3 months after the final dose of study treatment. Highly effective methods of contraception include: a. Implantable intrauterine device (IUD) or contraceptive system, b. Barrier methods of contraception: spermicide-containing condom or occlusive cap (uterine cap or cervix/fornix cap), and c. Recognized hormonal contraceptive methods: oral, injectable, or implantable. Female subjects using hormonal contraceptives must receive a stable dose of the same hormonal contraceptive product from the last menstrual period prior to randomization and must continue to use the same hormonal contraceptive product for the duration of the study treatment as well as for 3 months after the final dose of study treatment, d. Confirmed azoospermic vasectomy partner.
• Voluntarily agrees to, and signs, a written informed consent form, and is willing and able to comply with all aspects of the trial protocol, and the patient may withdraw consent at any time without prejudice.

• previous neoadjuvant or adjuvant therapy containing eribulin (anitrotinib may have been applied)
• patients in whom anitrotinib is contraindicated.
• patients with active symptomatic brain metastases or meningeal metastases.
• patients with active/refractory infections requiring ongoing anti-infective therapy.
• pulmonary lymphovascular dissemination resulting in pulmonary dysfunction requiring active therapy, including the use of oxygen.
• severe cardiovascular impairment (history of congestive heart failure greater than New York Heart Association (NYHA) class II), unstable angina pectoris or myocardial infarction within the past 6 months, or severe cardiac arrhythmias.
• Subjects with allogeneic organ transplants requiring immunosuppressive therapy.
• Subjects known to be positive for Human Immunodeficiency Virus (HIV).
• Subjects with prior malignant tumors other than breast, cervical carcinoma in situ, and non-melanoma skin cancer. Subjects with a prior malignancy other than breast cancer and non-melanoma skin cancer, unless the prior malignancy has been previously diagnosed and definitively treated for at least 5 years without evidence of subsequent recurrence.
• Subjects with pre-existing neuropathy > Grade 2.
• Subjects with hypersensitivity to chondroitin B and/or chemical derivatives of chondroitin B.
• Any medical condition that, in the opinion of the Investigator, makes a subject ineligible for entry into the study.
• Subjects with a known human immunodeficiency virus (HIV)-positive condition.
• Subjects with a known human immunodeficiency virus (HIV)-positive condition.

• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

The First Hospital of Jilin University

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Cancer Center, The First Affiliated Hospital of Jilin University, Changchun, Jilin Province, China

Changchun, Jilin, China

Countries

China

Central Contacts

Zheng Lv

Role: CONTACT

lvz@jlu.edu.cn

15804301705

Facility Contacts

jiuwei Cui

Role: primary

jdyycjw@163.com

15843073215

xu sun

Role: backup

Other Identifiers

2023-HS-061

Identifier Type: -

Identifier Source: org_study_id